• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
RUI Xue,YE Liuping,HU Shigao.Risk Analysis and Countermeasures on Responsibility- based GMP Compliance Inspection of High-Risk Drug Manufacturing Enterprises in Anhui Province[J].Journal Of Pharmaceutical Research,2024,43(10):1029-1034[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2645times   Download 2407次 QR Code for this article
Scan with your phone!
安徽省高风险药品生产企业依职责GMP符合性检查风险分析与对策
芮雪,叶六平,胡士高
Font:Larger+|Default|Smaller-
(安徽省药品审评查验中心,安徽 合肥 230051)
摘要:
为推动高风险药品生产企业持续符合药品生产质量管理规范,对近三年安徽省开展的高风险药品生产企业依职责GMP符合性检查的缺陷项目进行统计分析。共汇总缺陷项目1 408项,包括严重缺陷7项、主要缺陷88项、一般缺陷1 313项,主要分布于质量控制与质量保证、文件管理、无菌药品附录等方面。高风险药品生产企业应从落实主体责任、强化污染控制策略、建立长效培训机制、严格供应商管理、完善确认与验证、加强产品质量回顾分析等方面着手持续保障药品质量安全。
关键词:  高风险药品  GMP检查  风险分析
DOI:10.13506/j.cnki.jpr.2024.10.018
基金项目:盖茨基金项目资助(粉液双室袋产品检查指南课题研究)
Publication Date:October 30, 2024
Risk Analysis and Countermeasures on Responsibility- based GMP Compliance Inspection of High-Risk Drug Manufacturing Enterprises in Anhui Province
RUI Xue,YE Liuping,HU Shigao
(Anhui Center for Drug Evaluation and Inspection, Hefei 230051,China)
Abstract:
In order to ensure continued adherence of high-risk drug manufacturing enterprises to GMP, a statistical analysis was performed on the deficiencies identified during the responsibility-based GMP compliance inspections conducted in Anhui Province from 2021 to 2023. A total of 1 408 inspection defects were summarized, including 7 serious defects, 88 major defects and 1 313 general defects, which were mainly in the aspects of quality control and quality assurance, document management, sterile drug appendices, etc. High-risk drugs manufacturing enterprises should implement the main responsibility, strengthen contamination control strategy, establish long-term training mechanism, strictly manage suppliers, improve confirmation and verification and enhance product quality review analysis to continuously improve high-risk drugs quality and safety.
Key words:  High-risk drug  Gmp inspection  Risk analysis
Today's Visits:509    Total Visits:2383239
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.